In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optobionics Corp.

Latest From Optobionics Corp.

Start-Up News

Noteworthy news from medtech start-ups. This month we profile three emerging artificial retina developers: Nano Retina, 2C Tech Corp. and LambdaVision.

Medical Device

LambdaVision Inc.

Artificial retinal prostheses are poised to make a dramatic impact by restoring at least partial vision to people blinded by degenerative ophthalmic diseases. A number of companies are developing complex implantable microelectronic innovations, many with external hardware components, to stimulate the retina and overcome the photoreceptor cell deterioration that is the hallmark of these diseases. LambdaVision Inc. is taking a unique approach to restoring vision by developing a flexible, protein-based retinal implant designed to provide higher resolution and to be less surgically invasive than competing technologies.

Medical Device

Clinical Edge

Brief summaries of recent advances in device research and clinical trials, including a promising new retinal implant and new findings in the field of radiation therapy.
Medical Device

Visible Progress in Devices for Age-Related Macular Degeneration

A mere seven years ago, before the approval of Visudyne photodynamic therapy, patients losing their vision to age-related macular degeneration (AMD) were told that there was nothing that could be done for them. Today, AMD sufferers may choose from an assortment of drug treatments. Genentech's Lucentis will reach almost $1 billion in sales in its first year on the market, analysts predict, and it doesn't claim to do anything except slow down the progression of the disease. Moreover, the drug does this better than first-generation anti-VEGF drug Macugen. And if those options aren't enough--and they're not--a handful of start-ups developing device-based therapies are making significant progress by applying some highly innovative approaches. ScyFIX, for example, is applying electrical stimulation to halt the effects of AMD and possibly repair the damage done. NeoVista is applying radiation therapy to the back of the eye, an approach that could serve as an alternative to Lucentis and other drugs based on growth factors, which require frequent injections into the eye. Retina Implant has developed an implantable microchip that will stimulate intact nerve cells in the retina to recreate the sense of sight.
Medical Device Combination Products
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Optobionics Corp.
  • Senior Management
  • Alan Y Chow, MD, Pres. & CEO
  • Contact Info
  • Optobionics Corp.
    Phone: (630) 665-6026
    191 Palamino Place
    Wheaton, IL 60187
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register